On November 11, 2021 Shanghai De Novo Pharmatech reported achievement of important First-in-Human milestone in China in phase I Trials with the novel investigational STING agonist DN015089 (Press release, De Novo Pharmatech, NOV 11, 2021, View Source;NewsCateID=38&CateID=38 [SID1234649251]). This Phase Ia/Ib open-label, multi-center study is designed to investigate the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary antitumor activity of DN015089 monotherapy in Chinese patients with advanced solid tumors (CTR20212462).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!